Clinical trial · Interventional
Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy
NCT01768195CI-TRIAL-00025424unknownPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to identify the effect of prophylactic entecavir in HBsAg Positive lymphoma patients treated with rituximab-based immunochemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatitis B | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Entecavir prophylaxis | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Entecavir prophylaxis
- description
- Participants will initiate entecavir 0.5 mg/day orally on day 1 of the first course of immunochemotherapy and/or chemotherapy, and will be continued until 12 months after completion of the immunochemotherapy and/or chemotherapy.
- interventionNames
- Drug: Entecavir prophylaxis
Primary outcomes (1)
- measure
- the incidence of hepatitis B virus reactivation and hepatitis B virus reactivation related hepatitis
- timeFrame
- from the beginning of immunochemotherapy and/or chemotherapy to 24 months after the last cycle of immunochemotherapy and/or chemotherapy
Secondary outcomes (5)
- measure
- the incidence of hepatitis B virus virological response
- timeFrame
- from the beginning of immunochemotherapy and/or chemotherapy to 24 months after the last cycle of immunochemotherapy and/or chemotherapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * treatment-naive patients with B-cell lymphoma * HBsAg positive at baseline * treated with rituximab-based immunochemotherapy * life expectancy of more than 3 months Exclusion Criteria: * younger than 18 years old * HBsAg negative at baseline * pregnant or lactating women
References
Publications (0)
Data not yet available
No reference posted for this study.